Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades; however, high-risk patients still have poor outcomes. Many bispecific antibody therapies are currently under investigation for the treatment of myeloma, such as blinatumomab, teclistamab, talquetamab and cevostamab, and the chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel, became the first CAR-T therapy to receive FDA approval for the treatment of multiple myeloma in March 2021. With CAR-T and bispecific antibodies demonstrating deep and sustained remissions, the role of ASCT in the future treatment of myeloma has become a subject of debate.
In this podcast, Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, and Parameswaran Hari, MD, MRCP, MS, of the Froedtert Hospital Cancer Center, Milwaukee, WI, discuss the benefits and drawbacks of the two immunotherapeutic modalities, CAR-T and bispecific antibodies as a replacement for ASCT in multiple myeloma.
Harnessing the tumor microenvironment in lymphoma therapy
Induction therapy in myeloma: an ever-changing paradigm
Precision epigenetic therapy for B-cell lymphoma
Acute leukemia: pushing boundaries in disease management
iwAL 2019: looking to the future of acute leukemia therapy
CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma
MRD testing in multiple myeloma: new technology with promising clinical applications
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
Patient discussion at EHA 2018: CAR T-cells and MRD in CLL
CLL therapies today: novel agents, combinations & the future of the field
CAR T-cell therapy: where are we now and what’s in store for the future?
Focus on MRD: current landscape and future questions in hemonc
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Acute leukemias: is MRD already a surrogate for survival?
Revolutionary immunotherapies for lymphoma
Latest advances and current challenges in immunotherapies for lymphoma
The circle of CLL: from gene discovery to targeted treatment
Debate on the use of MRD for multiple myeloma management
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive